1. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial;Borchmann;ASH Annual Meeting Abstracts,2008
2. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG);Engert,2009
3. Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial;Engert,2010
4. Erratum: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386-2395)) New England Journal of Medicine 2005 744
5. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group;Behringer;Journal of Clinical Oncology,2005